Form 4: IN8BIO CFO Granted 75,000 Stock Options

IN8BIO's Chief Financial Officer, Patrick McCall, was granted 75,000 employee stock options with an exercise price of $1.96.

Summary

• Patrick McCall, Chief Financial Officer of IN8BIO, INC. (INAB), was granted 75,000 employee stock options.
• The options have an exercise price of $1.96 per share.
• The grant date for these options was February 4, 2026.
• The options will vest over time, with 25% vesting on February 4, 2027, and the remaining shares vesting in 36 equal monthly installments thereafter.
• The options are subject to Mr. McCall continuing to provide service to the company through each vesting date.
• The expiration date for these options is February 4, 2036.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The grant of stock options to the CFO is a routine but effective mechanism to align management's interests with shareholders, fostering long-term commitment and performance, though it does not directly impact current financial results.

Positives

• The grant of stock options aligns the Chief Financial Officer's financial interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages the CFO's continued service and commitment to the company's performance over several years.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders.

Future Outlook

The vesting schedule of the stock options indicates a forward-looking incentive structure designed to retain the Chief Financial Officer and align his performance with the company's long-term success, with vesting continuing over several years until 2030.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industries. This compensation strategy is widely used to attract, retain, and motivate top talent by linking their personal wealth directly to the company's stock performance, thereby aligning executive interests with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology sector frequently include significant equity components, such as stock options, to incentivize long-term performance and retention. While specific comparisons require detailed peer group analysis, the grant of 75,000 options to a CFO at an exercise price of $1.96 is within the typical range for a company of IN8BIO's stage and market capitalization, similar to grants observed at emerging biotech firms like 'BioXcel Therapeutics' or 'Kura Oncology' for their executive teams, where equity forms a substantial part of total compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the CFO's interests with shareholder value creation, potentially leading to better long-term performance. However, future exercise of these options could result in dilution.
• Employees: Specifically impacts the Chief Financial Officer's compensation structure, providing a significant equity incentive for continued service and performance.

Next Steps

• The options will begin vesting on February 4, 2027, with subsequent monthly vesting installments.
• Patrick McCall will continue to provide service to the company to fulfill the vesting conditions.

Key Dates

Keywords

IN8BIO, INAB, Patrick McCall, CFO, Stock Options, Employee Stock Option, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Vesting Schedule